Tokyo, Japan, July 18, 2017 --- JCR Pharmaceuticals Co., Ltd. (JCR) and Teijin Limited (Teijin) announced today that they have entered into co-development and license agreement regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan. DPCs are expected to be applied widely in various therapeutic fields based on their potential in modulating the immune system, protecting the nerve system and generating new blood vessels, as well as their likelihood of minimal risk of drug rejection.
JCR, as a leading biopharmaceutical company, has been engaged in the cell culture research and development, including proprietary work focused on regenerative medicine for many years. Teijin, which highly evaluates DPCs developed by JCR, has been strengthening its involvement in the regenerative medicine field, including through joint research on DPCs.
JCR and Teijin will leverage the joint research targeting the mass-culture method for DPCs. The two companies aim to develop an allogeneic regenerative medical product administered via intravenous injection in hopes of improving common activities of acute cerebral infarction (stroke) victims.
JCR will manufacture the investigative JTR-161 product for the clinical trials, while Teijin will conduct non-clinical and clinical studies and file the marketing approval application. Upon the marketing approval of JTR-161, JCR will be responsible for the manufacture and supply of the commercial product and Teijin will handle sales in Japan.
Shin Ashida, Chairman, President and CEO COO, JCR Pharmaceuticals Co., Ltd.
“JCR is a specialty pharmaceutical company that uses its proprietary biotechnologies to develop value-added novel treatments that address unmet medical needs. We are honored that Teijin has recognized our cell therapy and regenerative medicine technologies by entering into this relationship with us. JCR is determined to apply its original technology toward easing the suffering of patients afflicted with various illnesses.”
Hiroshi Uno, Senior Executive Officer, President, Healthcare Business of Teijin Group
“We are delighted to enter into this agreement with JCR. Regenerative medicine is one of the growth strategies of Teijin’s medium-term management plan. We hope to provide drugs for treating strokes with our newly added JTR-161 for acute strokes and SB623 for chronic strokes. Also, in combination with our rehabilitation business, we wish to offer comprehensive solutions for cerebral infarction treatment.”
Under the terms of agreement, JCR will receive upfront payments, milestone payments and royalties. JCR and Teijin plan to start clinical development in 2018. The companies will also pursue possibilities to expand the range of filing applications for indications other than cerebral infarction.
About JCR Pharmaceuticals
JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy,“Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY741.3 billion (USD 6.5 billion) and total assets of JPY 964.1 billion (USD 8.5 billion) in the fiscal year ending March 31, 2017.
+81 3 3506 4055
Information in the press releases is current on the date of the announcement.
It is subject to change without prior notice.